2Mogensen C E. Management of early nephropathy in dia- betic patients[ J]. Annu Rev Med, 1995,46:79-93.
3Hollenberg N K, Parving H H, Viberti G, et al. Albumi- nuria response to very high-dose valsartan in type 2 diabe- tes mellitus [ J ]. Hypertens, 2007,25 ( 9 ) : 1921-1926.
4Rosario R F, Prabhakar S. Lipids and diabetic nephropa- thy[J]. Curr Diab Rep, 2006,6(6) :455-462.
5Tamura Y, Murayama T, Minami M, et al. Differential effect of statius on diabetic nephropathy in db/db mice [J]. Int J Mol Med, 2011,28(5) :683-687.
6Nishikawa T, Matsuzawa Y, Suematsu S, et al. Effect of atorvastatin on aldosterone production induced by glu- cose, LDL or angiotensin II in human renal mesangial cells [ J ]. Arzneimittelforschung, 2010,60 ( 7 ) : 445 -451.
7Alber H F, Frick M, Stissenbacher A, et al. Effect of atorv- astatin on peripheral endothelial function and systemic in- flammatory markers in patients with stable coronary artery disease[J]. Wien Med Wochenschr, 2007,157(3) :73-78.
8Colhoun H M, Betteridge D J, Durrington P N, et al. Effects of atorvastatin on kidney outcomes and cardiovas- cular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS) [J]. Am J Kidney Dis, 2009,54(5):810-819.
9Herget-Rosenthal S, Marggraf O, Husing J, et al. Early detection of acute renal failure by serum cystatin C [ J ]. Kidney Int, 2004,66(3) :1115-1122.
10Marino M, Andrews D, Brown D, et al. Transcytosis of retinol-bingding protein across renal proximal tuble cell after megalin ( gp330 )-mediated endocytosis [ J ]. JAM soc Nephrol, 2001,12 ( 4 ) : 637-648.
